Skip to main content

Table 4 Initial therapy used to treat symptomatic patients diagnosed with Waldenström macroglobulinemia (WM) with only bone marrow involvement (BMWM) and those with extramedullary involvement (EMWM)

From: Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis

Type of therapy EMWM (n = 106) BMWM (n = 206)
n (%) n (%)
Treated for WM   
 Yes 94 (88.67) 146 (70.87)
 Observation only 8 (7.55) 44 (21.36)
 Alternative medicine 2 (1.89) 9 (4.37)
 Missing data 2 (1.89) 7 (3.40)
Initial treatment   
 Chemotherapy 20 (18.87) 23 (11.17)
 Targeted therapy 25 (23.58) 79 (38.35)
 Combination 49 (46.23) 44 (21.36)
Initial treatment with R   
 Yes 72 (67.92) 118 (57.28)
 No 22 (20.75) 28 (13.59)
Initial treatment with NA   
 Yes 35 (33.02) 61 (29.61)
 No 59 (55.67) 85 (41.26)
  1. R rituximab, NA nucleoside analogs